Skip to main content

Advertisement

Table 1 New approved drugs for the second-line treatment of patients with advanced NSCLC

From: Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?

Reference Patients Histotype Regimen Response Progression-free survival, months Median overall survival, months P
Reck et al. [3] 658 Adenocarcinoma Docetaxel + nintedanib vs. docetaxel + placebo 4.7% vs. 3.6% 4.0 vs. 2.8 12.6 vs. 10.3 0.0359
Garon et al. [4] 1253 All histologies Docetaxel + ramucirumab vs. docetaxel + placebo 23% vs. 14% 4.5 vs. 3.0 10.5 vs. 9.1 0.023
Brahmer et al [5] 272 Squamous Nivolumab vs. docetaxel 20% vs. 9% 3.5 vs. 2.8 9.2 vs. 6.0 <0.001
Borghaei et al. [6] 582 Adenocarcinoma Nivolumab vs. docetaxel 19% vs. 12% 2.3 vs. 4.2 12.2 vs. 9.4 0.002
Herbst et al. [7] 1034 All histologies Pembrolizumab 2 mg/kg vs. pembrolizumab 10 mg/kg vs. docetaxel 18% vs. 18% vs. 9% 3.9 vs. 4.0 vs. 4.0 10.4 vs. 12.7 vs. 8.5 0.0008 < 0.0001
Rittmeyer et al. [8] 287 All histologies Atezolizumab vs. docetaxel 14% vs. 13% 2.8 vs. 4.0 13.8 vs. 9.6 0.0003
Soria et al. [9] 795 Squamous Afatinib vs. erlotinib 6% vs. 3% 2.6 vs. 1.9 7.9 vs. 6.8 0.0077